题名

Discrimination of CD44 and Oct3/4 Expression in Pancreatic Adenocarcinoma from Benign Pancreatic Ducts in Small Biopsy Specimens

DOI

10.4077/CJP.2017.BAF446

作者

Ching-Chang Lee；Wu-Hsien Kuo；Chih-Kung Lin；Hong-Wei Gao；Wen-Chiuan Tsai

关键词

cancer stem cell ； CD44 ； Oct3/4 ； pancreatic carcinoma

期刊名称

The Chinese Journal of Physiology

卷期/出版年月

60卷2期（2017 / 04 / 30）

页次

81 - 88

内容语文

英文
中文摘要

Cluster of differentiation 44 (CD44) and octamer-binding transcription factor 3/4 (Oct3/4) are important factors influencing cancer stem cell (CSC) development, but their clinical applications on pancreatic cancer are still unknown. Here, we tested the hypothesis that expression of CD44 and Oct3/4 correlates with the clinicopathological parameters of pancreatic ductal adenocarcinomas (PDACs). Firstly, data on the mRNA expression levels in PDACs and normal pancreatic tissues were collected from Gene Expression Omnibus (GEO) repository datasets. Immunohistochemical analyses of CD44 and Oct3/4 were next performed in tissue microarrays of 80 surgical specimens derived from a Chinese population, which included 9 normal pancreatic ducts and 71 PDACs, amongst which 12 were well differentiated, 47 moderately differentiated, and 12 poorly differentiated. From the GEO results, mRNA expression levels of both CD44 and Oct3/4 were higher in PDACs than in normal pancreatic tissues. In addition, immunostaining scores of these biomarkers were higher in most PDACs than in non-neoplastic pancreatic ducts. The intensity of CD44 and Oct3/4 staining in normal pancreatic tissues was weak and limited to small areas. Although CD44 and Oct3/4 overexpression in PDACs tended to be associated with advanced histologic grades of PDACs, the correlation of CD44 and Oct3/4 expression with the American Joint Committee on Cancer (AJCC) pathological stage was not statistically significant. In conclusion, CD44 and Oct3/4 overexpression may imply malignant transformation of pancreatic ducts and could help pathologists make a more accurate diagnosis and decision on clear surgical margins.
主题分类 醫藥衛生 > 基礎醫學
参考文献
  1. Aruffo, A.,Stamenkovic, I.,Melnick, M.,Underhill, C.B.,Seed, B.(1990).CD44 is the principal cell surface receptor for hyaluronate.Cell,61,1303-1313.
  2. Bosman, F.T.,Carneiro, F.,Hruban, R.H.,Theise, N.D.(2010).World Health Organization Classification of Tumours of the Digestive System.Lyon:IARC Press.
  3. Campbell, P.J.,Yachida, S.,Mudie, L.J.,Stephens, P.J.,Pleasance, E.D.,Stebbings, L.A.,Morsberger, L.A.,Latimer, C.,McLaren, S.,Lin, M.L.,McBride, D.J.,Varela, I.,Nik-Zainal, S.A.,Leroy, C.,Jia, M.,Menzies, A.,Butler, A.P.,Teague, J.W.,Griffin, C.A.,Burton, J.,Swerdlow, H.,Quail, M.A.,Stratton, M.R.,Iacobuzio-Donahue, C.,Futreal, P.A.(2010).The patterns and dynamics of genomic instability in metastatic pancreatic cancer.Nature,467,1109-1113.
  4. Du, Z.,Jia, D.,Liu, S.,Wang, F.,Li, G.,Zhang, Y.,Cao, X.,Ling, E.A.,Hao, A.(2009).Oct4 is expressed in human gliomas and promotes colony formation in glioma cells.Glia,57,724-733.
  5. Fitzgerald, T.L.,McCubrey, J.A.(2014).Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment.Adv. Biol. Regul.,56,45-50.
  6. Gall, T.M.,Tsakok, M.,Wasan, H.,Jiao, L.R.(2015).Pancreatic cancer: current management and treatment strategies.Postgrad. Med. J.,91,601-607.
  7. Hu, Y.,Fu, L.(2012).Targeting cancer stem cells: a new therapy to cure cancer patients.Am. J. Cancer Res.,2,340-356.
  8. Hueng, D.Y.,Lin, G.J.,Huang, S.H.,Liu, L.W.,Ju, D.T.,Chen, Y.W.,Sytwu, H.K.,Chang, C.,Huang, S.M.,Yeh, Y.S.,Lee, H.M.,Ma, H.I.(2011).Inhibition of Nodal suppresses angiogenesis and growth of human gliomas.J. Neurooncol.,104,21-31.
  9. Ivanova, N.,Dobrin, R.,Lu, R.,Kotenko, I.,Levorse, J.,De-Coste, C.,Schafer, X.,Lun, Y.,Lemischka, I.R.(2006).Dissecting self-renewal in stem cells with RNA interference.Nature,442,533-538.
  10. Jiang, W.,Zhang, Y.,Kane, K.T.,Collins, M.A.,Simeone, D.M.,di Magliano, M.P.,Nguyen, K.T.(2015).CD44 regulates pancreatic cancer invasion through MT1-MMP.Mol. Cancer Res.,13,9-15.
  11. Jones, T.D.,Ulbright, T.M.,Eble, J.N.,Baldridge, L.A.,Cheng, L.(2004).OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma.Am. J. Surg. Pathol.,28,935-940.
  12. Jordan, C.T.,Guzman, M.L.,Noble, M.(2006).Cancer stem cells.N. Engl. J. Med.,355,1253-1261.
  13. Kekuda, R.,Prasad, P.D.,Wu, X.,Wang, H.,Fei, Y.J.,Leibach, F.H.,Ganapathy, V.(1998).Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta.J. Biol. Chem.,273,15971-15979.
  14. Lee, C.J.,Dosch, J.,Simeone, D.M.(2008).Pancreatic cancer stem cells.J. Clin. Oncol.,26,2806-2812.
  15. Li, C.,Heidt, D.G.,Dalerba, P.,Burant, C.F.,Zhang, L.,Adsay, V.,Wicha, M.,Clarke, M.F.,Simeone, D.M.(2007).Identification of pancreatic cancer stem cells.Cancer Res.,67,1030-1037.
  16. Ling, G.Q.,Chen, D.B.,Wang, B.Q.,Zhang, L.S.(2012).Expression of the pluripotency markers Oct3/4, Nanog and Sox2 in human breast cancer cell lines.Oncol. Lett.,4,1264-1268.
  17. Looijenga, L.H.,Stoop, H.,de Leeuw, H.P.,de Gouveia Brazao, C.A.,Gillis, A.J.,van Roozendaal, K.E.,van Zoelen, E.J.,Weber, R.F.,Wolffenbuttel, K.P.,van Dekken, H.,Honecker, F.,Bokemeyer, C.,Perlman, E.J.,Schneider, D.T.,Kononen, J.,Sauter, G.,Oosterhuis, J.W.(2003).POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors.Cancer Res.,63,2244-2250.
  18. Marhaba, R.,Zoller, M.(2004).CD44 in cancer progression: adhesion, migration and growth regulation.J. Mol. Histol.,35,211-231.
  19. Matsuoka, J.,Yashiro, M.,Sakurai, K.,Kubo, N.,Tanaka, H.,Muguruma, K.,Sawada, T.,Ohira, M.,Hirakawa, K.(2012).Role of the stemness factors sox2, oct3/4, and nanog in gastric carcinoma.J. Surg. Res.,174,130-135.
  20. Mimeault, M.,Batra, S.K.(2014).Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancers.Cancer Epidemiol. Biomarkers Prev.,23,234-254.
  21. Noguchi, K.,Eguchi, H.,Konno, M.,Kawamoto, K.,Nishida, N.,Koseki, J.,Wada, H.,Marubashi, S.,Nagano, H.,Doki, Y.,Mori, M.,Ishii, H.(2015).Susceptibility of pancreatic cancer stem cells to reprogramming.Cancer Sci.,106,1182-1187.
  22. Ohara, Y.,Oda, T.,Sugano, M.,Hashimoto, S.,Enomoto, T.,Yamada, K.,Akashi, Y.,Miyamoto, R.,Kobayashi, A.,Fukunaga, K.,Morishita, Y.,Ohkohchi, N.(2013).Histological and prognostic importance of CD44+/CD24+/EpCAM+ expression in clinical pancreatic cancer.Cancer Sci.,104,1127-1134.
  23. Orian-Rousseau, V.(2010).CD44, a therapeutic target for metastasising tumours.Eur. J. Cancer,46,1271-1277.
  24. Ponnusamy, M.P.,Batra, S.K.(2008).Ovarian cancer: emerging concept on cancer stem cells.J. Ovarian Res.,1,4.
  25. Ponnusamy, M.P.,Deb, S.,Dey, P.,Chakraborty, S.,Rachagani, S.,Senapati, S.,Batra, S.K.(2009).RNA polymerase II associated factor 1/PD2 maintains self-renewal by its interaction with Oct3/4 in mouse embryonic stem cells.Stem Cells,27,3001-3011.
  26. Reya, T.,Morrison, S.J.,Clarke, M.F.,Weissman, I.L.(2001).Stem cells, cancer, and cancer stem cells.Nature,414,105-111.
  27. Reynolds, R.B.,Folloder, J.(2015).Clinical management of pancreatic cancer.J. Adv. Pract. Oncol.,5,356-364.
  28. Roberts, N.J.,Klein, A.P.(2013).Genome-wide sequencing to identify the cause of hereditary cancer syndromes: with examples from familial pancreatic cancer.Cancer Lett.,340,227-233.
  29. Szklarczyk, D.,Franceschini, A.,Wyder, S.,Forslund, K.,Heller, D.,Huerta-Cepas, J.,Simonovic, M.,Roth, A.,Santos, A.,Tsafou, K.P.,Kuhn, M.,Bork, P.,Jensen, L.J.,von Mering, C.(2015).STRING v10: protein-protein interaction networks, integrated over the tree of life.Nucleic Acids Res.,43,D447-D452.
  30. Tai, M.H.,Chang, C.C.,Kiupel, M.,Webster, J.D.,Olson, L.K.,Trosko, J.E.(2005).Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis.Carcinogenesis,26,495-502.
  31. Trosko, J.E.(2006).From adult stem cells to cancer stem cells: Oct-4 Gene, cell-cell communication, and hormones during tumor promotion.Ann. N. Y. Acad. Sci.,1089,36-58.
  32. Vaz, A.P.,Ponnusamy, M.P.,Rachagani, S.,Dey, P.,Ganti, A.K.,Batra, S.K.(2014).Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells.Brit. J. Cancer,111,486-496.
  33. Wood, N.J.(2014).Pancreatic cancer: pancreatic tumour formation and recurrence after radiotherapy are blocked by targeting CD44.Nat. Rev. Gastroenterol. Hepatol.,11,73.
  34. Zöller, M.(2011).CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?.Nat. Rev. Cancer,11,254-267.
print cancel